AIMS: To investigate the dosage and duration of inhaled steroids prescribed to children and to compare the prescribed doses with recommended doses for the treatment of asthma in children. METHODS: For 2514 Dutch children aged 0-12 years who had used inhaled steroids in 2002, pharmacy dispensing data were obtained from the InterAction database, type of steroid (beclomethason, budesonide, fluticasone) and type of user (first time or existing) and the average prescribed doses according to age were determined and compared with the doses as recommended in the national Dutch Nederlands Huisartsen Genootschap (NHG) guideline. Furthermore, for all first-time users the duration of therapy with inhaled steroids was determined using a Kaplan-Meier analysis. RESULTS: The major findings were that: (i) overall 43% of children starting inhaled steroids were prescribed doses that are half the recommended dose or less; (ii) overall 8% of the children starting inhaled steroids were prescribed doses that were twice the recommended dose or more, up to 50% in the 12-year-olds fluticasone group; and (iii) only 8% of the children who started with inhaled steroids used them continuously for a full year. CONCLUSIONS: Doses of inhaled steroids for many children deviate from those recommended, with lower doses more frequently occurring than higher doses. Less than 10% of the children receive prescriptions for a prolonged period of time.
AIMS: To investigate the dosage and duration of inhaled steroids prescribed to children and to compare the prescribed doses with recommended doses for the treatment of asthma in children. METHODS: For 2514 Dutch children aged 0-12 years who had used inhaled steroids in 2002, pharmacy dispensing data were obtained from the InterAction database, type of steroid (beclomethason, budesonide, fluticasone) and type of user (first time or existing) and the average prescribed doses according to age were determined and compared with the doses as recommended in the national Dutch Nederlands Huisartsen Genootschap (NHG) guideline. Furthermore, for all first-time users the duration of therapy with inhaled steroids was determined using a Kaplan-Meier analysis. RESULTS: The major findings were that: (i) overall 43% of children starting inhaled steroids were prescribed doses that are half the recommended dose or less; (ii) overall 8% of the children starting inhaled steroids were prescribed doses that were twice the recommended dose or more, up to 50% in the 12-year-olds fluticasone group; and (iii) only 8% of the children who started with inhaled steroids used them continuously for a full year. CONCLUSIONS: Doses of inhaled steroids for many children deviate from those recommended, with lower doses more frequently occurring than higher doses. Less than 10% of the children receive prescriptions for a prolonged period of time.
Authors: M J Visser; D S Postma; L R Arends; T W de Vries; E J Duiverman; P L Brand Journal: Am J Respir Crit Care Med Date: 2001-12-01 Impact factor: 21.405
Authors: Taco B M Monster; Wilbert M T Janssen; Paul E de Jong; Lolkje T W de Jong-van den Berg Journal: Pharmacoepidemiol Drug Saf Date: 2002 Jul-Aug Impact factor: 2.890
Authors: Eric Schirm; Taco B M Monster; Robin de Vries; Paul B van den Berg; Lolkje T W de Jong-van den Berg; Hilde Tobi Journal: Pharmacoepidemiol Drug Saf Date: 2004-03 Impact factor: 2.890
Authors: Tjalling W de Vries; Hilde Tobi; Eric Schirm; Paul van den Berg; Eric J Duiverman; Lolkje T W de Jong-van den Berg Journal: Eur J Clin Pharmacol Date: 2005-12-20 Impact factor: 2.953
Authors: Stanley J Szefler; James F Chmiel; Anne M Fitzpatrick; George Giacoia; Thomas P Green; Daniel J Jackson; Heber C Nielsen; Wanda Phipatanakul; Hengameh H Raissy Journal: J Allergy Clin Immunol Date: 2013-11-28 Impact factor: 10.793
Authors: Dirkje S Postma; Richard Dekhuijzen; Thys van der Molen; Richard J Martin; Wim van Aalderen; Nicolas Roche; Theresa W Guilbert; Elliot Israel; Daniela van Eickels; Javaria Mona Khalid; Ron M C Herings; Jetty A Overbeek; Cristiana Miglio; Victoria Thomas; Catherine Hutton; Elizabeth V Hillyer; David B Price Journal: Allergy Asthma Immunol Res Date: 2017-03 Impact factor: 5.764